does anyone know the status of international sales. They have inked some impressive deals with UK, Ireland, Japan, and probably more in the works. The weak dollar should support their efforts in gaining an entre into those lucrative markets. This is the quarter that sales should start to show as they load the pipeline. obviously their are costs associated with international expansion, however they should be rapidly covered as patients who are a good fit for this therapy will adopt it quickly. After the first year of being available internationally it should develop into a market that resembles the US. One of education and having to earn the rest of the market. I am not familiar with UK/IRE, but the japanese medical market is much more evolved and superior to ours in quickly supporting and reimbursing for truly improved therapies.